TapanM.KadiaMD

Oncology • Houston, TX

Hematologic Oncology

Associate Professor, Leukemia Department

Join to view full profile

Dr. Kadia is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Kadia's full profile

Already have an account?

Office
1515 Holcombe Blvd
Houston, TX 77030
Phone+1 713-792-6161

Fax+1 713-563-7746

Education & Training

University of Texas Health Science Center at HoustonFellowship, Hematology and Medical Oncology, 2005 - 2008
Baylor College of MedicineResidency, Internal Medicine, 2001 - 2005
Rutgers Robert Wood Johnson Medical SchoolClass of 2001

Certifications & Licensure

FL State Medical License 2021 - Present
TX State Medical License 2004 - 2026
OK State Medical License 2020 - 2021

Clinical Trials

Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of Nelarabine in Patients With Relapsed/Refractory Lymphoid Malignancies Start of enrollment: 2010 Jun 08
Completed
Phase 1
Alemtuzumab in Myelodysplastic Syndrome (MDS), Aplastic Anemia, and T-Cell Large Granular Lymphocytic Leukemia (T-GL) Start of enrollment: 2010 Aug 01
Terminated
Phase 2
Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS) Start of enrollment: 2012 Feb 07
Recruiting
Phase 2
Methylprednisolone, Horse Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, and/or Pegfilgrastim or Pegfilgrastim Biosimilar in Treating Patients With Aplastic Anemia or Low or Intermediate-Risk Myelodysplastic Syndrome Start of enrollment: 2012 Jun 25
Recruiting
Phase 2
Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia Start of enrollment: 2014 May 19
Recruiting
Phase 2
Lenalidomide in Treating Patients With High Risk Acute Myeloid Leukemia in Remission Start of enrollment: 2014 Nov 13
Completed
Phase 2
Phase II Study of Fludarabine, Cytarabine (ARA-C) and Erwinase IV in Patients With Relapsed or Refractory Hematologic Malignancies Start of enrollment: 2018 May 01
Withdrawn
Phase 2
Palbociclib and Sorafenib, Decitabine, or Dexamethasone in Treating Patients With Recurrent or Refractory Leukemia Start of enrollment: 2017 Jul 25
Recruiting
Phase 1
Venetoclax, Cladribine, Low Dose Cytarabine, and Azacitidine in Treating Patients With Previously Untreated Acute Myeloid Leukemia Start of enrollment: 2018 Oct 25
Recruiting
Phase 2
Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid Leukemia Start of enrollment: 2018 Oct 29
Recruiting
Phase 2
TK216 and Decitabine in Treating Patients With Relapsed and Refractory Acute Myeloid Leukemia Start of enrollment: 2019 Mar 31
Withdrawn
Phase 1
A Clinical Trial of CK0801 (a New Drug) in Patients With Bone Marrow Failure Syndrome (BMF) Start of enrollment: 2019 May 30
Active, not recruiting
Phase 1
Itacitinib and Alemtuzumab in Treating Patients With T-Cell Prolymphocytic Leukemia Start of enrollment: 2020 Jan 15
Active, not recruiting
Phase 1
AZA + Venetoclax as Maintenance Therapy in Patients With AML in Remission Start of enrollment: 2019 Sep 13
Recruiting
Phase 2
Fludarabine, Cytarabine, and Pegcrisantaspase for the Treament of Relapsed or Refractory Leukemia Start of enrollment: 2021 Apr 09
Active, not recruiting
Phase 1
APG-2575 Study of Safety, Tolerability ,PK/PD in Patients With Hematologic Malignancies Start of enrollment: 2018 Aug 07
Recruiting
Early Phase 1
Roles: Principal Investigator, Contact
Hu8F4 in Treating Patients With Advanced Hematologic Malignancies Start of enrollment: 2019 Jan 31
Active, not recruiting
Phase 1
Roles: Contact, Principal Investigator
Decitabine Alone or in Combination With Venetoclax, Gilteritinib, Enasidenib, or Ivosidenib as Maintenance Therapy for the Treatment of Acute Myeloid Leukemia in Remission Start of enrollment: 2021 Oct 25
Recruiting
Phase 1
Roles: Principal Investigator, Contact
A Study of APG-115 Alone or Combined With Azacitidine in Patients With AML, CMML, or MDS Start of enrollment: 2020 Dec 04
Recruiting
Phase 1, Phase 2
Roles: Contact, Principal Investigator
Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage Start of enrollment: 2019 Nov 22
Recruiting
Phase 3
Roles: Contact, Principal Investigator
Galinpepimut-S Versus Investigator's Choice of Best Available Therapy for Maintenance in AML CR2/CRp2 Start of enrollment: 2021 Feb 08
Active, not recruiting
Phase 3
Roles: Contact
Tegavivint for the Treatment of Relapsed or Refractory Leukemia Start of enrollment: 2021 Sep 27
Active, not recruiting
Phase 1
Roles: Contact, Principal Investigator
Uproleselan, Cladribine, and Low Dose Cytarabine for the Treatment of Patients With Treated Secondary Acute Myeloid Leukemia Start of enrollment: 2021 Jun 11
Active, not recruiting
Phase 1, Phase 2
Roles: Principal Investigator, Contact
ABC008 in Subjects With T-cell Large Granular Lymphocytic Leukemia (T-LGLL) Start of enrollment: 2022 Sep 28
Recruiting
Phase 1, Phase 2
Roles: Principal Investigator, Contact
Join now to see all

Publications & Presentations

PubMed

2 citations
Results of the Simultaneous Combination of Ponatinib and Blinatumomab in Philadelphia Chromosome-Positive ALL.
Hagop Kantarjian, Nicholas J Short, Fadi G Haddad, Nitin Jain, Xuelin Huang
Journal of Clinical Oncology. 2024-12-20
Mayo Genetic Risk Models for Newly Diagnosed Acute Myeloid Leukemia Treated With Venetoclax + Hypomethylating Agent.
Naseema Gangat, Azeem Elbeih, Nour Ghosoun, Kristen McCullough, Fnu Aperna
American Journal of Hematology. 2024-12-13
Clinical interrogation of TP53 aberrations and its impact on survival in patients with myeloid neoplasms.
Jayastu Senapati, Sanam Loghavi, Guillermo Garcia-Manero, Guillin Tang, Tapan Kadia
Haematologica. 2024-12-12

Journal Articles

Response Kinetics and Factors Predicting Survival in Core-Binding Factor Leukemia
Hagop Kantarjian, Gautam Borthakur, Tapan Kadia, Nature

Abstracts/Posters

Final Results of Phase 2 Clinical Trial of LCL161, a Novel Oral SMAC Mimetic/IAP Antagonist, for Patients with Intermediate to High Risk Myelofibrosis
Tapan M. Kadia, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Title: 12 Versus 8 Prophylactic Intrathecal (IT) Chemotherapy Administration Decrease Incidence of Central Nervous System (CNS) Relapse in Patients (pts) with Newly Di...
Tapan M. Kadia, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Combined Ibrutinib and Venetoclax for First-Line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL)
Tapan M. Kadia, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Outcomes of Relapsed or Refractory Acute Myeloid Leukemia after Frontline Hypomethylating Agent with Venetoclax Regimens
Tapan M. Kadia, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
A 20-Year Review of Imatinib in Chronic Phase Chronic Myeloid Leukemia Patients after Failure with Interferon Therapy
Tapan M. Kadia, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Phase II Study of the Hyper-CVAD Regimen in Combination with Ofatumumab (HCVAD-O) As Frontline Therapy for Adult Patients (pts) with CD20-Positive B-Cell Acute Lymphob...
Tapan M. Kadia, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Venetoclax Added to Ibrutinib in High-Risk CLL Achieves a High Rate of Undetectable Minimal Residual Disease. [RTS1]
Tapan M. Kadia, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Ten-Day Decitabine with Venetoclax (DEC10-VEN) in Acute Myeloid Leukemia: Updated Results of a Phase II TrialClinically Relevant Abstract
Tapan M. Kadia, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Sequential Combination of Inotuzumab Ozogamicin (InO) with Low-Intensity Chemotherapy (Mini-hyper-CVD) with or without Blinatumomab Is Highly Effective in Patients (pt...
Tapan M. Kadia, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Outcomes of Patients with Acute Myeloid Leukemia (AML) with Myelodysplasia Related Changes (AML-MRC) Are Dependent on Diagnostic Criteria and Therapy
Tapan M. Kadia, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Outcomes of Patients with Suboptimal /Warning Response to Tyrosine Kinase Inhibitors: A Comparison of the 2009 and 2013 Guidelines of the European Leukemianet
Tapan M. Kadia, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Updated Results of a Phase II Study of Reduced-Intensity Chemotherapy with Mini-Hyper-CVD in Combination with Inotuzumab Ozogamicin, with or without Blinatumomab, in O...
Tapan M. Kadia, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Phase II Study of Blinatumomab in Patients with B-Cell Acute Lymphoblastic Leukemia (B-ALL) with Positive Measurable Residual Disease (MRD)
Tapan M. Kadia, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Outcome of Patients (Pts) with Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) without 3-Month Complete Molecular Response (CMR)
Tapan M. Kadia, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Fludarabine, Cytarabine, G-CSF and Gemtuzumab Ozogamicin (FLAG-GO) Regimen Results in Better Molecular Response and Relapse-Free Survival in Core Binding Factor Acute ...
Tapan M. Kadia, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Combining CDK2/9 Inhibitor CYC065 with Venetoclax, a BCL2 Inhibitor, to Treat Patients with Relapsed or Refractory AML or MDS
Tapan M. Kadia, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Machine Learning Prediction for Complete Response to Hypomethylating Agents with or without Additional Agents in Patients with Newly Diagnosed Myelodysplastic Syndrome
Tapan M. Kadia, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Phase 2 Study of Ruxolitinib (RUX) in Combination with 5-Azacitidine (AZA) in Patients (pts) with Myelofibrosis
Tapan M. Kadia, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Determinants of Outcomes of FLT3mut Acute Myeloid Leukemia with First Salvage Therapy
Tapan M. Kadia, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Characteristics and Outcomes of Therapy-Related Versus De Novo Acute Myeloid Leukemia with Normal Karyotype
Tapan M. Kadia, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Effectiveness of Bosutinib in Chronic Myeloid Leukemia (CML) Who Have Received Multi Tyrosine Kinase Inhibitors (TKIs)
Tapan M. Kadia, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Discontinuation of Tyrosine Kinase Inhibitors (TKIs) in Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL)
Tapan M. Kadia, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Activity of Multiple Targetable Therapies in FLT3-Mutated (mu) Acute Myeloid Leukemia (AML) Patients (pts) with Concurrent Isocitrate Dehydrogenase Mutation (IDHm)
Tapan M. Kadia, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Genomic Context and TP53 Allele Frequency Define Prognostic Subgroups and Response Outcomes in TP53 Mutated Myelodysplastic Syndromes
Tapan M. Kadia, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Safety and Efficacy of Combined Ruxolitinib and Thalidomide in Patients with Myelofibrosis: A Phase II Study
Tapan M. Kadia, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Join now to see all

Lectures

Less Is More
ASCO Annual Meeting 2019 - Chicago, IL - 6/3/2019
Venetoclax Combined with Cladribine + Low Dose AraC (LDAC) Alternating with 5-Azacytidine Produces High Rates of Minimal Residual Disease (MRD) Negative Complete Remis...
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
An Oral Combination Study of Novel Nucleoside Analogue Sapacitabine and BCL2 Inhibitor Venetoclax to Treat Patients with Relapsed or Refractory AML or MDS
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Phase 2 Study of Ruxolitinib (RUX) in Combination with 5-Azacitidine (AZA) in Patients (pts) with Myelofibrosis
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Evaluation of Romyelocel-L Myeloid Progenitor Cells to Decrease Infections in De Novo AML Patients Receiving High-Dose Ara-C-Based Induction Therapy
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Chemoimmunotherapy with Inotuzumab Ozogamicin Combined with Mini-Hyper-CVD, with or without Blinatumomab, for Newly Diagnosed Older Patients with Philadelphia Chromoso...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Mechanisms Underlying Superior Efficacy of Co-Targeting BET Proteins and Anti-Apoptotic BCL2 or MCL1 Protein Against AML Blast Progenitor Cells
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Inotuzumab Ozogamicin in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) Vs. Standard Intensive Chemotherapy (hyper-CVAD) As Frontline Therapy for Older P...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Final Results of Phase I/II Study of Selinexor (SEL) with Sorafenib in Patients (pts) with Relapsed and/or Refractory (R/R) FLT3 Mutated Acute Myeloid Leukemia (AML)
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Mutational and Clonal Landscape of Acute Myeloid Leukemia with Myelodysplastic Related Changes
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Final Report of a Phase II Study of Guadecitabine (SGI-110) in Patients (pts) with Previously Untreated Myelodysplastic Syndrome (MDS)
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Pan-Myeloid Leukemia Analysis: Machine Learning-Based Approach to Predict Phenotype and Clinical Outcomes Using Mutation Data
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Diverse Landscape of TET2 Variants in MDS and AML
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Five-Day Versus Ten-Day Schedules of Decitabine in Older Patients with Newly Diagnosed Acute Myeloid Leukemia: Results of a Randomized Phase II Study
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Novel BET Protein Degrader-Based Combinations Exert Lethality Against Human AML Resistant to BET Inhibitors Due to Increased Activity of β-Catenin-TCF7L2- MYC Axis
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Evolutionary Action Score of Missense TP53 Mutations Can Predict Outcome in Patients with Myelodysplastic Syndrome and Acute Myeloid Leukemia
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Efficacy and Safety of Pomalidomide in Combination with Prednisone in Patients with Myelofibrosis and Anemia – Final Results of a Prospective Phase 2 Study
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Combined Ibrutinib and Venetoclax in Patients with Treatment-Naïve High-Risk Chronic Lymphocytic Leukemia (CLL)
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (iFCG) for Firstline Treatment of Patients with CLL with Mutated IGHV and without TP53 Aberrations
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Impact of Clonal Hematopoiesis of Indeterminate Potential (CHIP) Associated Mutations and Risk of Comorbidities in Patients with Myelodysplastic Syndrome
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Double Immune Checkpoint Inhibitor Blockade with Nivolumab and Ipilimumab with or without Azacitidine in Patients with Myelodysplastic Syndrome (MDS)
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Nivolumab (Nivo) maintenance (maint) in high-risk (HR) acute myeloid leukemia (AML) patients.
2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
Join now to see all

Authored Content

A Phase I/II Study of Selinexor (SEL) with Sorafenib in Patients (Pts) with Relapsed and/or Refractory (R/R) FLT3 Mutated Acute Myeloid Leukemia (AML)October 2017
Clinical Experience of Venetoclax Combinations for Relapsed/Refractory Myeloid MalignanciesOctober 2017
The Combination of Quizartinib with Azacitidine or Low Dose Cytarabine Is Highly Active in Patients (Pts) with FLT3-ITD Mutated Myeloid Leukemias: Interim Report of a Phase I/II TrialOctober 2017

Press Mentions

Clinical Challenges: Optimizing Infection Prophylaxis in AMLSeptember 15th, 2021
Add-on Venetoclax Promising in Younger, Fit AML PatientsJuly 30th, 2021
Trial Launches to Evaluate GlycoMimetics’ Uproleselan Added to Cladribine plus Low-Dose Cytarabine in AML PatientsJuly 22nd, 2021
Join now to see all